Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) has agreed a $512 million settlement in a class-action law suit in which a company it owns was accused of delaying the launch of Provigil (modafinil).
Cephalon, which was acquired by Teva in 2011 for $6.8 billion, was accused of entering into pay-for-delay agreements with generic drugmakers to keep generic formulations of Provigil off the market until 2012. The law suit was originally filed with drug wholesalers and retailers in 2006.
Denise Bradley, a spokeswoman for Teva, said the company is “pleased with the terms of the settlement.” This settlement amount represents the largest payment ever to drug buyers over claims that companies initially sought to delay generic therapies’ entrance to the market. According to court documents, Mylan and Ranbaxy are not included in the settlement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze